By Torpedo / 27th May, 2019

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate Terbium-161 (T1/2 = 6.89 days; Eβav = 154 keV) in combination with PSMA-617 as a potentially more effective therapeutic alternative to Lutetium-177-PSMA-617, due to the abundant co-emission of conversion and Auger electrons, resulting in an improved absorbed dose profile.